PHARMACY

FDA panel recommends approval for J&J Type 2 diabetes drug

BY Alaric DeArment

RARITAN, N.J. — A panel of Food and Drug Administration experts has recommended approval for an experimental Type 2 diabetes drug made by Johnson & Johnson, the drug maker said.

J&J said the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee had recommended approval for canagliflozin, which the company plans to market under the name brand Invokana. The FDA is not required to follow the votes of advisory committees when deciding whether or not to approve a drug, but usually does.

The drug is a once-daily pill for treating Type 2 diabetes, the most common form of diabetes, in adults, and works by blocking the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.


Find us on Facebook for even more insight, analysis and the latest in drug store news.

keyboard_arrow_downCOMMENTS

Leave a Reply

M.Clint says:
Apr-01-2013 08:13 pm

At last, they have made up their mind and approved the release of that drug. Diabetics will be very happy of this decision. - The Balancing Act Lifetime

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
PHARMACY

Consumables, drugs to see slower market growth in 2013, study finds

BY Alaric DeArment

NEW YORK — Growth in the consumer products market is likely to slow down over the next five years, while pharmacy retailers will see a profit windfall due to the generic drug cycle, according to a new report.

The report, from Guggenheim Securities, found that the $1.8 trillion market for consumables — which the firm uses to describe goods like foods, beverages, drugs and other medical products — will grow by 3-3.5%, compared with 4.5% over the prior two decades, due to a combination of economics and demographics. At the same time, consumer interest in a "value and convenience" model was driving market share to low-cost retailers like Costco, Kroger, Dollar General, Family Dollar and Five Below.

In particular, food and beverages grew by 0.5% in November 2012, compared with 3.5% in the first half of 2012, while drugs and other medical products grew by 3.2%, down from 4.7% in the first half of 2012.

Overall, the report said, retailers whose competitive positioning allows them to suffer less will fare better price-wise, while those that don’t require a healthy top line to succeed, such as drug stores, will outperform. Guggenheim issued "Buy" ratings for the stock of Dollar General, Family Dollar, CVS, Walgreens, Rite Aid, Kroger and Five Below.


Find us on Facebook for even more insight, analysis and the latest in drug store news.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...
PHARMACY

Chronic disease patients want online services from drug companies, study finds

BY Alaric DeArment

NEW YORK — Demand among consumers for online services from drug companies to help manage chronic conditions is strong, according to a new study from healthcare market research firm Manhattan Research.

The ePharma Consumer — 2012 study, based on an online survey of 6,607 adults conducted in the last three months of 2012, found that 30% of online consumers with a chronic condition and 38% of caregivers are interested in registering for a patient-support program that would give access to a range of services, such as financial assistance, meal plans and recipes, condition-management tools and a hotline of registered nurses. Current adoption of such programs varies considerably from one condition to another; for example, 41% of online patients with multiple sclerosis used one. In addition, 75% of online consumers using online pharma patient support programs said they feel confident their prescriptions are right for them.

"Patients are interested in patient support programs from pharma, and they don’t necessarily mind registering for access," Manhattan Research VP research Monique Levy said. "At the same time, pharma isn’t top-of-mind as a destination, so marketers must consider partnering with other health resources such as general health websites, pharmacies and hospitals in an effort to gain traction for these programs."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

http://www.drugstorenews.com/join-RHP?refcode=WEBLG11001

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?

View Results

Loading ... Loading ...